{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:33:12Z","timestamp":1770435192420,"version":"3.49.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>At present, voriconazole (VOR) is the drug of first choice for treating invasive pulmonary aspergillosis (IPA). However, particularly in advanced stages of disease and in the severely immunocompromised host, the mortality remains substantial. The combination of VOR with an echinocandin may improve the therapeutic outcome. We investigate here whether combining VOR and anidulafungin (ANI) in advanced IPA in transiently neutropenic rats results in a higher therapeutic efficacy. Since VOR is metabolized more rapidly in rodents than in humans, dosage adjustment for VOR is necessary to obtain an area under the plasma concentration-time curve (AUC) in rodents that is equivalent to that of humans. In this study, the pharmacokinetics of VOR and ANI in rats were elucidated, and dosage schedules were applied that produced AUCs similar to those of humans. The developed dose schedules were well tolerated by the rats, without effects on renal and hepatic functions. VOR showed excellent efficacy in early IPA (100% rat survival). In advanced IPA, VOR was less efficacious (50% rat survival), whereas a significant decrease in galactomannan concentrations in lungs and sera was found in surviving rats. ANI administered in advanced IPA resulted in 22% rat survival, and the serum concentrations of fungal galactomannan were slightly but not significantly decreased. The addition of ANI to VOR did not result in significantly increased therapeutic efficacy in advanced IPA, resulting in 67% rat survival and a significant decrease in galactomannan concentration in serum. In conclusion, VOR monotherapy is therapeutically effective in the treatment of advanced-stage IPA and superior to the use of ANI. Combining both agents does not significantly improve the therapeutic outcome.<\/jats:p>","DOI":"10.1128\/aac.01556-08","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T02:10:51Z","timestamp":1235441451000},"page":"2005-2013","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin"],"prefix":"10.1128","volume":"53","author":[{"given":"Wendy W. J.","family":"van de Sande","sequence":"first","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron A. A.","family":"Mathot","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy, Clinical Pharmacology Unit, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian T.","family":"ten Kate","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"van Vianen","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehri","family":"Tavakol","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J. A.","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Section Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma A. J. M.","family":"Bakker-Woudenberg","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200412000-00005"},{"key":"e_1_3_2_3_2","first-page":"991","volume":"4","year":"2003","unstructured":"Andes, D. 2003. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr. Opin. Investig. Drugs.4:991-998.","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-07"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1187-1192.2003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780600913224"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg367"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.4.1434-1438.2000"},{"key":"e_1_3_2_12_2","unstructured":"NONMEM users guide. V. Introductory guide. 1994"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9041-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.673"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00958.x"},{"key":"e_1_3_2_16_2","unstructured":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. 2002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.970-978.2004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.744"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.608"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005281234"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg261"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2146\/ajhp060584","volume":"64","year":"2007","unstructured":"Greene, R. E., J. Mauskopf, C. S. Roberts, T. Zyczynski, and H. T. Schlamm. 2007. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am. J. Health Syst. Pharm.64:2561-2568.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_2_24_2","first-page":"967","volume":"29","year":"2001","unstructured":"Kerbusch, T., R. A. Mathot, H. J. Keizer, G. P. Kaijser, J. H. Schellens, and J. H. Beijnen. 2001. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab. Dispos.29:967-975.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2564-2568.2002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3697-3701.2005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22348"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14787210.4.2.325","volume":"4","year":"2006","unstructured":"Morrison, V. A. 2006. Echinocandin antifungals: review and update. Expert Rev. Anti-Infect. Ther.4:325-342.","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.696"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-07"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/375420"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3572-3574.2005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.731"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767020-00009"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm123"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000202421.94822.f7"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.601-604.2001"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1228-z"},{"key":"e_1_3_2_41_2","unstructured":"Med. Mycol."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00536-07"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl015"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/424465"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/hcm035","volume":"100","year":"2007","unstructured":"Zmeili, O. S., and A. O. Soubani. 2007. Pulmonary aspergillosis: a clinical update. Q. J. Med.100:317-334.","journal-title":"Q. J. Med."},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1582-4934.2002.tb00186.x","volume":"6","year":"2002","unstructured":"Zuber, R., E. Anzenbacherova, and P. Anzenbacher. 2002. Cytochromes P450 and experimental models of drug metabolism. J. Cell Mol. Med.6:189-198.","journal-title":"J. Cell Mol. Med."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01556-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01556-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:23:18Z","timestamp":1645474998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01556-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1128\/AAC.01556-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01556-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"2008-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}